

ABRIDGED AUDITED CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025

Recovering with Resilience, Advancing with Purpose



DIRECTORS COMMENTARY AND COMPANY OVERVIEW

The Board of Directors of Africure (the “Board”) is pleased to present the audited results for the year ended 31 March 2025.

Africure Pharmaceuticals Ltd is engaged in the manufacturing, trading, and distribution of pharmaceutical formulations, with a primary focus on oral dosage forms in essential drug categories. Operating across multiple African countries, Africure plays a vital role in improving access to affordable, high-quality medicines in emerging healthcare markets.

Several African markets experienced constrained liquidity, resulting in lower procurement by private sector distributors and reduced stockholding across supply chains. Pharmacies and wholesalers adopted a cautious approach to inventory management, negatively affecting primary sales volumes.

The generic pharmaceutical space saw intensified price competition, coupled with increased working capital requirements led by longer cycles.

HIGHLIGHTS OF PERFORMANCE

- Africure went through a complex business operating scenario in the FY 2024–25 due to tight liquidity, compressed demand from private markets, need for increased inventory levels and longer working capital cycles.
- These dynamics led to a marginal increase in revenue of 10% versus the previous year, as stockholding levels at various points in the supply chain remained low and buying cycles lengthened.
- Private market sales were challenging this year due to price competition and distributors taking a longer time to liquidate stock, however Africure managed to upside the revenue stream through government orders which grew by 27% this year.
- EBITDA grew to USD 3.73 million, representing a 13% EBITDA margin and a 14% increase over the previous year.
- Gross Margins moderated to 38% (from 40%) due to a shift in market mix.
- Operating Expenses remained stable at USD 8.48 million (vs USD 8.41 million).
- Total Assets stood at USD 58.44 million (vs USD 60.76 million), primarily due to depreciation on long-term fixed assets.
- Debt-to-Equity Ratio increased to 0.8x (from 0.6x), mainly due to increased shareholding at subsidiary levels, resulting in reduced consolidated reserves.
- The Board has not declared any dividend for the period and continues to reinvest profits to maintain growth momentum.

We believe that the business has gained traction and is on the road to recovery. The markets we serve have shown a very exciting growth in macro fundamentals and this encourages us to grow steadily. Management is taking sufficient action to infuse optimum working capital for the business through various initiatives, to ensure there are no missed opportunities or lost sales.

Finally, and of note, we have successfully completed our planned Quality & ESG compliance initiatives and audits in line with our commitment to maintain high standards of quality and compliance.

CURRENT BUSINESS OUTLOOK

- The primary emphasis remains on achieving annual budgeted performance to reinforce the Group’s operating fundamentals.
- Africure currently holds a confirmed order book of USD 10 million, reflecting strong traction in its target markets. A key strategic priority is the timely execution and conversion of these orders into revenue, ensuring adherence to committed delivery schedules and optimizing production cycles.
- Bringing the Ethiopian manufacturing facility into full operations is central to Africure’s regional production strategy. Management is prioritizing all necessary steps—regulatory compliance, staffing, and working capital alignment—to ensure commercialisation.
- To support business continuity and order fulfillment, the Group is actively pursuing interim funding options. These funds will be deployed to clear critical supplier payments, boost inventory levels, and ensure adequate liquidity to meet operational demands while sustaining long-term business momentum.
- Africure is in the process of forging partnerships with antiretroviral (ARV) manufacturers for contract manufacturing. These collaborations are expected to enhance capacity utilization, improve cost absorption, and diversify the product and revenue base, further solidifying the Company’s position as a regional manufacturing partner of choice.

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

All the amounts are in USD unless otherwise stated

	31-Mar-25 Group	31-Mar-24 Group
ASSETS		
Non-current assets		
Goodwill	2,635,871	2,607,969
Property plant and equipment	15,670,285	15,744,934
Intangible assets	104,580	162,453
Right of use assets	2,487,717	2,624,627
Capital work in progress	7,294,453	8,034,076
Deferred tax asset	-	186,419
Total non-current assets	28,192,906	29,360,478
Current assets		
Inventories	9,272,823	10,855,793
Trade receivables	16,380,489	16,053,857
Cash and cash equivalents	1,325,587	1,511,754
Other assets	3,265,425	3,200,792
Total current assets	30,244,324	31,622,196
Total assets	58,437,230	60,982,674
EQUITY AND LIABILITIES		
EQUITY		
Equity share capital and share premium	10,881,853	10,881,853
Share application money pending allotment	7,762,672	-
Retained earnings	1,173,731	14,208,874
Other reserves	(4,259,196)	(4,827,146)
Capital and reserves attributable to owners of Africure Pharmaceuticals Ltd	15,559,060	20,263,581
Non-controlling interests	(306,133)	(3,305,874)
Non-current liabilities		
Borrowings	20,435,749	16,853,087
Operating lease liabilities	3,904,360	3,195,689
Deferred tax liabilities	1,419,098	-
Total non-current liabilities	25,759,207	20,048,776
Current liabilities		
Borrowings	5,059,160	11,317,227
Trade and accounts payables	10,659,208	11,532,791
Other liabilities	1,123,538	782,505
Operating lease liabilities	192,358	192,358
Current tax liabilities	390,832	151,310
Total current liabilities	17,425,096	23,976,191
Total Equity and liabilities	58,437,230	60,982,674
Net Asset Value	1.65	2.15

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

	31-Mar-25 Group	31-Mar-24 Group
Revenue	29,766,051	26,796,900
Other income	991,905	1,472,891
	30,757,956	28,269,791
Cost of raw-materials and finished goods	18,542,567	15,752,734
Employee benefit expenses	4,089,522	4,432,447
Other expenses	4,394,354	3,977,884
	27,026,443	24,163,065
Profit before finance cost, depreciation and tax	3,731,513	4,106,726
Finance costs	(3,116,740)	(2,324,999)
Depreciation and amortisation	(1,512,644)	(1,537,879)
(Loss)/Profit before income tax	(897,871)	243,848
Income tax expense		
Current tax	(830,647)	(608,067)
Deferred tax	(26,596)	(40,940)
(Loss)/Profit for the year from continued operations	(1,755,114)	(405,159)
Loss for the year from discontinued operations	(1,059,424)	-
	(2,814,538)	(405,159)
(Loss)/Profit attributable to		
Owners of the Company	(2,966,877)	(281,628)
Non-controlling interests	152,339	(123,531)
Earnings per share for profit attributable to the ordinary equity holders of the company		
Basic earnings per share	(0.3)	(0.04)
Diluted earnings per share	(0.3)	(0.04)
Weighted average number of shares	9,417,500	9,417,500

CONSOLIDATED STATEMENT OF CASHFLOWS

	31-Mar-25 Group	31-Mar-24 Group
Net cash flow from operating activities	2,855,809	2,724,811
Net cash flow used in investing activities	-503,589	-1,085,357
Net cash flow used in financing activities	-2,538,387	-2,528,840
Net (decrease)/increase in cash and cash equivalents	-186,167	-889,386
Cash and cash equivalents at the beginning of the year	1,511,754	2,401,141
Cash and cash equivalents at the end of the year	1,325,587	1,511,754

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

	Group					
	Share capital and share premium	Retained earnings	Other Reserves	Equity attributable to owners of the Company	Non-Controlling interests	Total equity
Balance as at 1-Apr-23	10,881,853	14,490,503	(2,559,526)	22,812,830	(3,182,343)	19,630,487
Profit for the period	-	(281,628)	(2,267,620)	(2,549,248)	(123,531)	(2,672,779)
Balance as at 1-Apr-24	10,881,853	14,208,875	(4,827,146)	20,263,582	(3,305,874)	16,957,708
Loss for the year	-	(2,966,877)	567,950	(2,398,927)	152,339	(2,246,588)
Other reserves	-	-	-	-	541,809	541,809
Proposed allotment of equity shares for non cash consideration	7,762,672	(7,762,672)	-	-	-	-
Transactions with shareholders holding non-controlling interest	-	(2,305,595)	-	(2,305,595)	2,305,595	-
Balance as at 31-Mar-25	18,644,525	1,173,731	(4,259,196)	15,559,060	(306,131)	15,252,929

NOTES TO THE ACCOUNTS

- The total number of ordinary shares in issue by the Company is 9,417,500 and the number of preference shares in issue is 1,930.
- The Company is required to publish its abridged consolidated audited financial results for the year ended 31st March 2025 in terms of the Listing Rule 12.14 of the SEM.
- The abridged audited consolidated financial statements for the year ended 31 March 2025 (“abridged audited consolidated financial statements”) have been prepared in accordance with the measurement and recognition requirements of IFRS, , the SEM Listing Rules using the same accounting policies as those of the audited consolidated financial statements for the year ended 31 March 2024, except for new standards as applicable/ as amended.
- The Company’s external auditors, RSM (Mauritius) LLP have issued an unmodified audit opinion on the consolidated financial statements for the year ended 31 March 2025. These abridged audited consolidated financial statements were approved by the Board on 30 July 2025.
- Copies of the abridged audited consolidated financial statements are available free of charge, upon request at the Registered Office of the Company at c/o Ocorian Corporate Services (Mauritius) Limited, 6th Floor, Tower A, 1 Exchange square, Wall Street, Ebene, Mauritius.
- This communiqué is issued pursuant to SEM Listing Rules 11.3 and 12.14. The Board accepts full responsibility for the accuracy of the information contained in this communiqué.

Contact Person: Mr Vashish Bisnathsing.

For further information please contact:

Perigeum Capital Ltd
SEM Authorised
Representative and Sponsor

Ocorian Coporate Services
(Mauritius) Limited
Company Secretary

